alfa

FDA Approves Drug Elosulfase Alfa (Vimizim™) for Mucopolysaccharidosis (MPS IVA)

By: Erica Dimitropoulos Co-Copy Editor [Content- Focused]  - On February 14, 2014, elosulfase alfa (Vimizim™) became an FDA-approved enzyme replacement therapy…

12 years ago

Solving the HCV Enigma: Current and Future Drug Therapy for Hepatitis C

By: Tamara Yunusova, Senior Staff Editor - Approximately 3.2 million Americans have chronic hepatitis C infection.1 While acute cases are…

13 years ago

The Pathology of Pure Red Cell Aplasia

By: Neal Shah, Co Editor-In-Chief - Pure Red Cell Aplasia (PRCA), also known as erythroblastopenia, is characterized by a suppression…

14 years ago

Xigris: A Worldwide Withdrawal

By: Khilna Patel, Pharm.D. Candidate c/o 2012 - On October 25 of this year, Eli Lilly and Company announced a…

14 years ago